Was Kristen Williams’ Pacira (PCRX) share sale made under a Rule 10b5-1 trading plan?

Yes, the Form 4 states the sale was executed under a Rule 10b5-1 trading plan. The plan was previously adopted on September 10, 2025, indicating the transaction timing was pre-arranged rather than discretionary.

Pacira (PCRX) CAO sells 10,259 shares under pre-set 10b5-1 trading plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pacira BioSciences Chief Administrative Officer Kristen Williams sold 10,259 shares of common stock in an open-market trade at $22.27 per share on June 4, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.

One day earlier, on June 3, 2026, 8,528 shares were withheld at $22.32 per share to cover tax obligations upon vesting of a restricted stock unit award, which is a non-market, compensation-related event. After these transactions, Williams directly holds 167,062 Pacira shares.

Insider Trade Summary 10b5-1

Net Seller: 10,259 shares ($228,468)

Net Sell 2 txns

Insider WILLIAMS KRISTEN

Role Chief Administrative Officer

Sold 10,259 shs ($228K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,259	$22.27	$228K
Tax Withholding	Common Stock	8,528	$22.32	$190K

Holdings After Transaction: Common Stock — 167,062 shares (Direct, null)

Footnotes (1)

Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Key Figures

Open-market sale: 10,259 shares at $22.27 Tax withholding shares: 8,528 shares at $22.32 Shares held after transactions: 167,062 shares +2 more

5 metrics

Open-market sale 10,259 shares at $22.27 Common Stock sold on June 4, 2026

Tax withholding shares 8,528 shares at $22.32 Withheld for RSU tax obligations on June 3, 2026

Shares held after transactions 167,062 shares Direct common stock ownership after reported trades

Net reported open-market activity 10,259 shares sold Net-sell direction from transaction summary

Rule 10b5-1 plan adoption date September 10, 2025 Date Williams adopted trading plan

Key Terms

Rule 10b5-1 trading plan, restricted stock unit award, tax-withholding disposition, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock unit award financial

"Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award."

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition","transaction_code_description": "Payment of exercise price or tax liability..."

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

open-market sale financial

"transaction_action": "open-market sale","transaction_code_description": "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 05:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILLIAMS KRISTEN

(Last)

(First)

(Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Administrative Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		F		8,528⁽¹⁾	D	$22.32	177,321	D
Common Stock	06/04/2026		S		10,259⁽²⁾	D	$22.27	167,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Remarks:

	/s/ Kristen Williams	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pacira BioSciences (PCRX) insider Kristen Williams report on this Form 4?

Kristen Williams reported selling 10,259 Pacira BioSciences shares at $22.27 each in an open-market transaction. She also reported shares withheld for taxes on vested restricted stock units and now directly holds 167,062 Pacira common shares following these transactions.

How many Pacira BioSciences (PCRX) shares did Kristen Williams sell and at what price?

Kristen Williams sold 10,259 Pacira BioSciences common shares at $22.27 per share. This was an open-market sale disclosed in the Form 4, and it occurred on June 4, 2026, under a previously adopted Rule 10b5-1 trading plan.

Why were 8,528 Pacira BioSciences (PCRX) shares disposed of in Kristen Williams’ Form 4?

The 8,528 shares were withheld by Pacira to cover tax withholding obligations when a restricted stock unit award vested. This F-code transaction is a tax-withholding disposition, not an open-market sale, and reflects standard handling of equity-based compensation.

How many Pacira BioSciences (PCRX) shares does Kristen Williams hold after these transactions?

After the reported sale and tax withholding, Kristen Williams directly holds 167,062 Pacira BioSciences common shares. This post-transaction balance is shown in the Form 4 and provides context for the size of her reported transactions.